June. 13, 2024 |
|
June. 13, 2024 |
|
jRCT2033240156 |
Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting |
|
Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting |
Kaneko Takehiko |
||
Heartseed Inc |
||
1-2-3, Shibaura, Minato-ku Tokyo |
||
+81-3-6380-1068 |
||
chiken@heartseed.jp |
||
Toiawase Madoguchi |
||
Heartseed Inc |
||
1-2-3, Shibaura, Minato-ku Tokyo |
||
+81-3-6380-1068 |
||
chiken@heartseed.jp |
Recruiting |
June. 13, 2024 |
||
10 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
Subjects who participated in the HS-001-01 study and were transplanted with HS-001CS and who were able to obtain voluntary consent in writing for inclusion in this clinical trial. |
||
Patients judged by the Investigator to be ineligible shall not be included in the Clinical Trial. |
||
20age old over | ||
80age old under | ||
Both |
||
Heart failure with ischemic heart disease |
||
To take immunosuppressant tacrolimus or other immunosuppressant |
||
Ischemic heart disease, Heart Failure, Coronary artery bypass grafting (CABG) |
||
Safety |
||
Safety |
Heartseed Inc |
Tokyo Womens Medical University Institutional Review Board | |
8-1,Kawada-cho,Shinjuku-ku,Tokyo,Japan, Tokyo | |
+81-3-3353-8111 |
|
Approval | |
No |
|
none |